Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Reports Q4 revenue $56.2M, consensus $52.25M. “Strong revenue growth for Fanapt is putting us on a significant growth trajectory for 2025 and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...